[Suppression of experimental inflammation by anti-fungal agent liranaftate in mice]

Nihon Ishinkin Gakkai Zasshi. 2010;51(1):7-11. doi: 10.3314/jjmm.51.7.
[Article in Japanese]

Abstract

To evaluate the anti-inflammatory activity of the thiocarbamate antifungal agent liranaftate, the edema and the neutrophil accumulation detected by the activity of neutrophil marker enzyme, myeloperoxidase (MPO), were examined following application of liranaftate to mouse ears with inflammation induced by phorbol 12-myristate 13-acetate (PMA). Topical 20 microl administration of liranaftate in a dose-range between 1-4% suppressed the increase in ear thickness 6 hr after PMA application dose-dependently. Similarly, it decreased the weight increase of an ear section after 24 hr dose-dependently. More than 1% of liranaftate also suppressed augmentation of MPO activity of the ear section. This and histological observation indicate that liranaftate treatment suppressed neutrophil accumulation in PMA-applied ear lesion. From these results, we discussed that liranaftate might suppress inflammatory symptoms caused by trychophytosis in a clinical condition.

Publication types

  • English Abstract

MeSH terms

  • Administration, Topical
  • Animals
  • Antifungal Agents / administration & dosage*
  • Antifungal Agents / pharmacology
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Mice
  • Mice, Inbred ICR
  • Naphthalenes / administration & dosage*
  • Naphthalenes / pharmacology
  • Neutrophil Infiltration / drug effects
  • Otitis / chemically induced
  • Otitis / drug therapy*
  • Otitis / microbiology
  • Peroxidase
  • Phorbol Esters
  • Pyridines / administration & dosage*
  • Pyridines / pharmacology
  • Thiocarbamates / administration & dosage*
  • Thiocarbamates / pharmacology
  • Tinea

Substances

  • Antifungal Agents
  • Naphthalenes
  • Phorbol Esters
  • Pyridines
  • Thiocarbamates
  • phorbol-12-myristate
  • liranaftate
  • Peroxidase